Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rapt Therapeutics Inc (NQ: RAPT )

2.230 +0.110 (+5.19%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Rapt Therapeutics Inc

< Previous 1 2 3 4 Next >
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q2 2024
RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
Via Benzinga
What's Going On With Dermatitis-Focused RAPT Therapeutics Stock On Thursday?
RAPT Therapeutics closes Phase 2 trials for zelnecirnon in atopic dermatitis & asthma following FDA clinical hold due to liver failure. 
Via Benzinga
Exposures Product Safety
RAPT Therapeutics: Q4 Earnings Insights
Via Benzinga
Recap: RAPT Therapeutics Q3 Earnings
Via Benzinga
Analyst Ratings for RAPT Therapeutics
Via Benzinga
Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q1 2024
RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
3 Biotech Stocks to Dump Before They Go to Zero
These biotech stocks to sell are burning through cash at an alarming rate and seem destined for zero, making them prime targets for selling. 
Via InvestorPlace
RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q4 2023
RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Rivian Automotive Reports Q4 Loss, Joins Etsy, Lucid Group And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures trading higher by around 2% on Thursday. 
Via Benzinga
What's Going On With RAPT Therapeutics Stock On Wednesday?
Latest developments in RAPT Therapeutics as FDA places clinical hold on Phase 2b trial for zelnecirnon in dermatitis and asthma. Stock rebounds and analyst downgrades. 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why International Flavors & Fragrances Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of International Flavors & Fragrances Inc. (NYSE: IFF) fell during Wednesday’s session after the company reported mixed fourth-quarter financial results and reduced its expected quarterly... 
Via Benzinga
Stocks Slip Ahead Of Fed Minutes, Nvidia Earnings
Stocks are lower today, with the Nasdaq Composite Index (IXIC) leading the losses as investors reassess a potentially overvalued tech sector. 
Via Talk Markets
Topics Economy Stocks
Exposures Interest Rates US Equities
Crude Oil Moves Lower; Summit Therapeutics Shares Plummet
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling over 200 points on Tuesday. The Dow traded down 0.18% to 38,557.86 while the NASDAQ fell 1.30% to 15,570.84. The... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter results. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Is Inflammatory Disease/Oncology-Focused RAPT Therapeutics Shares Tumbling Today?
FDA places clinical hold on RAPT Therapeutics' Phase 2 trials for zelnecirnon in atopic dermatitis and asthma. 
Via Benzinga
Exposures Product Safety
Rapt Therapeutics Crashes 65% After Unexpected Liver Failure Sidelines Two Tests
The FDA put studies in eczema and asthma treatment on clinical hold. 
Via Investor's Business Daily
Exposures Product Safety
Dow Dips Over 100 Points; US Leading Economic Index Falls In January
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 1.5% on Tuesday. The Dow traded down 0.35% to 38,494.51 while the NASDAQ fell 1.51% to 15,537.95. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Rebounds; Nasdaq Drops Triple Digits
Nvidia stock is sliding ahead of tomorrow's earnings report 
Via Talk Markets
Topics Stocks
Exposures US Equities
Nasdaq Down 1%; Capital One Set To Buy Discover
U.S. stocks traded lower this morning, with the Nasdaq Composite falling around 150 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.05% to 38,607.53 while the NASDAQ fell... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
7 ‘Strong Buy’ Biotech Stocks to Rejuvenate Your Portfolio
Dive into these seven strong buy biotech stocks, handpicked by Wall Street, to inject vigor into your investment game. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.